EMA supports encorafenib plus binimetinib combination

medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization be given for the combination of encorafenib and binimetinib in patients with BRAF V600-mutated unresectable or metastatic melanoma.

The efficacy of the combined BRAF inhibitor and the MEK inhibitor regimen in this population was demonstrated by overall survival findings from the COLUMBUS trial .

The joint therapy has also been approved by the US FDA for this indication.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See also:

• Encorafenib-binimetinib a new option for BRAF-mutated melanoma
• Expert comment